Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy

Abstract This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy. To this end, from 2004 to 2016, 322 patients with surgically resected and pathologically confirmed isocitrate dehy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tae Hoon Roh, Ju Hyung Moon, Hun Ho Park, Eui Hyun Kim, Chang-Ki Hong, Se Hoon Kim, Seok-Gu Kang, Jong Hee Chang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c2151e0ede9f40f5bc078c0b974e815f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2151e0ede9f40f5bc078c0b974e815f
record_format	dspace
spelling	oai:doaj.org-article:c2151e0ede9f40f5bc078c0b974e815f2021-12-02T16:32:08ZAssociation between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy10.1038/s41598-020-67697-w2045-2322https://doaj.org/article/c2151e0ede9f40f5bc078c0b974e815f2020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-67697-whttps://doaj.org/toc/2045-2322Abstract This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy. To this end, from 2004 to 2016, 322 patients with surgically resected and pathologically confirmed isocitrate dehydrogenase (IDH)-wildtype GBM who received TMZ-based chemoradiotherapy were analysed. The patients were divided into two groups based on whether LEV was used as an anticonvulsant both at the time of surgery and the first visit thereafter. The median overall survival (OS) and progression-free survival (PFS) were compared between the groups. The OS was 21.1 and 17.5 months in the LEV (+) and LEV (−) groups, respectively (P = 0.003); the corresponding PFS was 12.3 and 11.2 months (P = 0.017). The other prognostic factors included age, extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and Karnofsky Performance Status (KPS) score. The multivariate analysis showed age (hazard ratio [HR], 1.02; P < 0.001), postoperative KPS score (HR 0.99; P = 0.002), complete tumour resection (HR 0.52; P < 0.001), MGMT promoter methylation (HR 0.75; P < 0.001), and LEV use (HR 0.72; P = 0.011) were significantly associated with OS. In conclusion, LEV use was associated with prolonged survival in patients with GBM treated with concurrent TMZ chemoradiotherapy.Tae Hoon RohJu Hyung MoonHun Ho ParkEui Hyun KimChang-Ki HongSe Hoon KimSeok-Gu KangJong Hee ChangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tae Hoon Roh Ju Hyung Moon Hun Ho Park Eui Hyun Kim Chang-Ki Hong Se Hoon Kim Seok-Gu Kang Jong Hee Chang Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
description	Abstract This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy. To this end, from 2004 to 2016, 322 patients with surgically resected and pathologically confirmed isocitrate dehydrogenase (IDH)-wildtype GBM who received TMZ-based chemoradiotherapy were analysed. The patients were divided into two groups based on whether LEV was used as an anticonvulsant both at the time of surgery and the first visit thereafter. The median overall survival (OS) and progression-free survival (PFS) were compared between the groups. The OS was 21.1 and 17.5 months in the LEV (+) and LEV (−) groups, respectively (P = 0.003); the corresponding PFS was 12.3 and 11.2 months (P = 0.017). The other prognostic factors included age, extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and Karnofsky Performance Status (KPS) score. The multivariate analysis showed age (hazard ratio [HR], 1.02; P < 0.001), postoperative KPS score (HR 0.99; P = 0.002), complete tumour resection (HR 0.52; P < 0.001), MGMT promoter methylation (HR 0.75; P < 0.001), and LEV use (HR 0.72; P = 0.011) were significantly associated with OS. In conclusion, LEV use was associated with prolonged survival in patients with GBM treated with concurrent TMZ chemoradiotherapy.
format	article
author	Tae Hoon Roh Ju Hyung Moon Hun Ho Park Eui Hyun Kim Chang-Ki Hong Se Hoon Kim Seok-Gu Kang Jong Hee Chang
author_facet	Tae Hoon Roh Ju Hyung Moon Hun Ho Park Eui Hyun Kim Chang-Ki Hong Se Hoon Kim Seok-Gu Kang Jong Hee Chang
author_sort	Tae Hoon Roh
title	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
title_short	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
title_full	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
title_fullStr	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
title_full_unstemmed	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
title_sort	association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/c2151e0ede9f40f5bc078c0b974e815f
work_keys_str_mv	AT taehoonroh associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT juhyungmoon associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT hunhopark associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT euihyunkim associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT changkihong associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT sehoonkim associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT seokgukang associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy AT jongheechang associationbetweensurvivalandlevetiracetamuseinglioblastomapatientstreatedwithtemozolomidechemoradiotherapy
_version_	1718383833393397760

Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy

Ejemplares similares